Precision medicine company ImpriMed announced it is expanding its services to include human oncology.
The goal is to provide drug response prediction for common blood cancers such as newly diagnosed multiple myeloma or acute myeloid leukemia.
ImpriMed’s human precision medicine service combines genomic analysis, in vitro drug sensitivity testing, and machine learning to target complex blood cancers.
New research data from the company Results of the naïve non-Hodgkin lymphoma treatment trial will be presented at the EHA-SfPM meeting in Copenhagen, Denmark, September 25-27.
“ImpriMed’s expansion of precision medicine services from veterinary medicine to human oncology is a significant milestone in our mission to transform cancer care,” ImpriMed CEO Dr. Sungwon Lim said in a statement.
“By empowering oncologists and researchers to use AI-based technologies to predict treatment outcomes, we can ensure that every patient receives truly personalized care. Through our expansion into contract research organization services, we aim to support the development of new cancer treatments and more personalized therapies, bringing hope to more patients on their cancer journey.”
The bigger trend
In August, ImpriMed announced the results of a study on a new cell sizing method for feline lymphoma. Veterinary. By improving the accuracy of cell size assessment, ImpriMed’s technology could revolutionize veterinary oncology, providing more reliable prognostic insights and improving treatment planning and patient outcomes, according to research data.
In May, the company launched ImpriMed Drug Response Predictions, an AI service that provides personalized drug response predictions for canine patients with lymphoma or leukemia. DRP is an addendum to the company’s personalized prediction profiles, featuring an “Immune Profile” report that provides clonality and immunophenotypic data.
